(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056314 A2

(51) International Patent Classification[7]: A61K

(21) International Application Number:
PCT/US2003/040538

(22) International Filing Date:
17 December 2003 (17.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/322,266	17 December 2002 (17.12.2002)	US
60/493,226	7 August 2003 (07.08.2003)	US
60/501,170	8 September 2003 (08.09.2003)	US
60/510,785	8 October 2003 (08.10.2003)	US
60/517,290	4 November 2003 (04.11.2003)	US
60/518,812	10 November 2003 (10.11.2003)	US

(71) Applicant *(for all designated States except US)*: **NASTECH PHARMACEUTICAL COMPANY INC.** [US/US]; 3450 Monte Villa Parkway, Bothell, WA 98021-8906 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **QUAY, Steven, C.** [US/US]; 23632 Hwy 99, Ste. F PMB 454, Edmonds, WA 98026-9224 (US). **BRANDT, Gordon** [US/US]; 790 Kalmia Ct., Issaquah, WA 98027 (US). **KLEPPE, Mary, S.** [US/US]; P.O. Box 1535, Kingston, WA 98346 (US). **MACEVILLY, Conor, J.** [US/US]; 3046 N.W. 60th Street, Seattle, WA 98107 (US).


(74) Agent: **LUNN, Paul, G.**; Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA 98021-8906 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY



(57) Abstract: Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C_{max}) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

WO 2004/056314 A2

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.